Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report)'s stock price fell 3.5% on Friday . The company traded as low as $16.14 and last traded at $16.50. 11,425 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 208,577 shares. The stock had previously closed at $17.10.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on SION. Guggenheim started coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $45.00 target price for the company. TD Cowen started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating for the company. Finally, Stifel Nicolaus started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price objective for the company.
Check Out Our Latest Stock Report on SION
Sionna Therapeutics Stock Down 5.0 %
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Recommended Stories
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
